Biosency has raised funds for further development
Biosency has completed a fundraising to develop a software for predictive diagnosis.
Biosency is a French MedTech company focused on changing the way clinicians and patients manage chronic obstructive pulmonary disease (COPD). The company provides innovative, connected and patient-focused remote monitoring solutions to analyze long-term trends of vital signs which are of critical importance to reduce readmission rates by adjusting medication.
Oaklins’ team in France acted as the exclusive advisor to Biosency.
Talk to the deal team
Related deals
The Providence Projects has been acquired by UKAT Group
Celebrity-success rehabilitation center, The Providence Projects, has joined The UK Addiction Treatment (UKAT) Group, backed by Sullivan Street Equity Partners.
Learn moreSt. Claraspital AG has been acquired by University Hospital Basel
University Hospital Basel (USB) has acquired St. Claraspital AG, expanding its network of specialized care and integrated services. With St. Claraspital’s strong community presence, expertise in acute and rehabilitation medicine and established outpatient clinics, this merger enhances USB’s ability to provide seamless, patient-centered treatment across the continuum of care. The completion of the transaction is subject to clearance by the Swiss Competition Commission (COMCO).
Learn moreRAM Infotechnology has acquired Interoperability Group with support from Keensight Capital
RAM Infotechnology (RAM-IT) has acquired Interoperability Group, a leading Dutch provider of healthcare IT solutions, with the support of Keensight Capital, a leading European growth buy-out investor specializing in technology and healthcare.
Learn more